Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LLY
stocks logo

LLY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
17.61B
+30.15%
7.087
+33.21%
16.91B
+32.84%
7.198
+115.52%
18.18B
+16.87%
7.723
+22.4%
Estimates Revision
The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 3.06% over the past three months. During the same period, the stock price has changed by 47.56%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.06%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.65%
In Past 3 Month
Stock Price
Go Up
up Image
+47.56%
In Past 3 Month
Wall Street analysts forecast LLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1012 USD with a low forecast of 700.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast LLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1012 USD with a low forecast of 700.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
3 Hold
0 Sell
Strong Buy
Current: 1030.050
sliders
Low
700.00
Averages
1012
High
1500
Current: 1030.050
sliders
Low
700.00
Averages
1012
High
1500
Scotiabank
initiated
$1,165
2025-11-12
Reason
Scotiabank
Price Target
$1,165
2025-11-12
initiated
Reason
Scotiabank initiated coverage of Eli Lilly with an Outperform rating and $1,165 price target.
Citi
Buy
maintain
2025-11-12
Reason
Citi
Price Target
2025-11-12
maintain
Buy
Reason
Citi raised the firm's price target on Eli Lilly to $1,500 from $1,250 and keeps a Buy rating on the shares. The firm sees Lilly's "domination" of the weight loss category accelerating following last week's agreement with the U.S. government for Medicare and Medicaid access. Citi sees an over $40B peak sales opportunity for Lilly's weight loss treatments and increased 2026 estimates.
Freedom Capital
Ilya Zubkov
Buy
to
Hold
downgrade
$750 -> $950
2025-11-10
Reason
Freedom Capital
Ilya Zubkov
Price Target
$750 -> $950
2025-11-10
downgrade
Buy
to
Hold
Reason
Freedom Capital analyst Ilya Zubkov downgraded Eli Lilly to Hold from Buy with a price target of $950, up from $750. Eli Lilly delivered "one of the strongest quarters in its history," says the analyst, who notes that strong performance and upward revisions to guidance have prompted the firm to raise revenue estimates. However, the firm is downgrading its rating due to current valuation levels.
Leerink
Market Perform -> Outperform
upgrade
$886
2025-11-10
Reason
Leerink
Price Target
$886
2025-11-10
upgrade
Market Perform -> Outperform
Reason
Leerink upgraded Eli Lilly to Outperform from Market Perform with a price target of $1,104, up from $886. The firm expects multiple waves of obesity treatment adoption drivers, led by significantly expanded Medicare and Medicaid access by January 2027 and Lilly's launches of orforglipron, retatrutide, and eloralintide to strengthen the company's leadership position, the analyst tells investors. The firm, which increased its 2026-2030E EPS by 4-9% annually, boosted its five-year revenue compound annual growth view from 12% to 15%.
UBS
Buy
maintain
$895
2025-11-07
Reason
UBS
Price Target
$895
2025-11-07
maintain
Buy
Reason
UBS raised the firm's price target on Eli Lilly to $1,080 from $895 and keeps a Buy rating on the shares. The firm updated its model following the Q3 earnings report.
Citi
Buy
upgrade
2025-11-07
Reason
Citi
Price Target
2025-11-07
upgrade
Buy
Reason
Citi raised the firm's price target on Eli Lilly to $1,250 from $1,190 and keeps a Buy rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Eli Lilly and Co (LLY.N) is 34.12, compared to its 5-year average forward P/E of 40.14. For a more detailed relative valuation and DCF analysis to assess Eli Lilly and Co 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
40.14
Current PE
34.12
Overvalued PE
52.09
Undervalued PE
28.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
30.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
37.93
Undervalued EV/EBITDA
22.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
20.15
Current PS
1021.70
Overvalued PS
113.41
Undervalued PS
-73.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LLY News & Events

Events Timeline

(ET)
2025-11-17
08:23:28
Novo introduces a $199 monthly self-pay option for Wegovy and Ozempic.
select
2025-11-17
08:10:50
Novo Nordisk Offers Lower Cash-Pay Price for Obesity Drug Compared to Lilly, According to Bloomberg
select
link
2025-11-13 (ET)
2025-11-13
15:51:01
Investors intend to stage a protest vote regarding the changes to the Novo Nordisk board, according to Reuters.
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-18SeekingAlpha
PinnedEli Lilly's donanemab receives approval in India for treating Alzheimer's disease.

  • Approval of Donanemab: Eli Lilly’s Alzheimer’s drug, donanemab, has received approval from India’s drug regulator and is set to launch in the coming months.

  • Target Patient Group: The drug is aimed at individuals with mild cognitive impairment and those in the early stages of Alzheimer’s-related dementia.

  • Pricing Considerations: The cost of donanemab in India is yet to be determined, influenced by factors such as local manufacturing and regulatory aspects.

  • Comparison to U.S. Pricing: In the United States, donanemab is priced at approximately $32,000 annually, which translates to around Rs 28.34 lakh per year.

[object Object]
Preview
9.0
05:00 AMNASDAQ.COM
Why Big Pharma Stays in the Weight Loss Game: Who Will Prevail in the Next Battle?

  • Market Growth Potential: The GLP-1 weight loss market is projected to reach $100 billion by 2030, with weight loss pills potentially capturing 25% of the market share in the long term.

  • FDA Approval Timeline: Eli Lilly and Novo Nordisk are competing to gain FDA approval for their oral GLP-1 versions, expected by the end of 2025, which could revolutionize weight loss treatment.

  • Investment Considerations: Eli Lilly currently has a higher price-to-earnings ratio and offers a quarterly dividend, while Novo Nordisk is seen as more reasonably priced but faces pressure to regain market leadership.

  • Regulatory and Market Challenges: The future of GLP-1 drugs may be impacted by long-term effects, regulatory changes, and price reductions, which could affect overall market size and revenue growth.

[object Object]
Preview
7.0
04:06 AMCNBC
Meta's significant antitrust victory, Salesforce finalizes its deal, and the iPhone's strong appeal in China

  • Market Performance: Stocks continued to decline, with the S&P 500 nearing its worst losing streak since August, influenced by drops in major tech stocks like Amazon and Microsoft, as well as concerns over AI valuations.

  • Salesforce Acquisition: Salesforce completed its $8.3 billion acquisition of Informatica ahead of schedule, signaling confidence in the integration, although concerns remain about AI's impact on its core business.

  • Meta Antitrust Case: A federal judge ruled in favor of Meta Platforms in an antitrust case, stating that the FTC failed to prove Meta's monopoly in social networking, which positively affected Meta's stock.

  • Apple's Market Share: iPhone sales surged in China, with Apple capturing 25% of the smartphone market, driven by strong demand for the iPhone 17, leading to a slight increase in Apple's stock.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Eli Lilly and Co (LLY) stock price today?

The current price of LLY is 1030.05 USD — it has increased 0.82 % in the last trading day.

arrow icon

What is Eli Lilly and Co (LLY)'s business?

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).

arrow icon

What is the price predicton of LLY Stock?

Wall Street analysts forecast LLY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1012 USD with a low forecast of 700.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Eli Lilly and Co (LLY)'s revenue for the last quarter?

Eli Lilly and Co revenue for the last quarter amounts to 17.60B USD, increased 53.87 % YoY.

arrow icon

What is Eli Lilly and Co (LLY)'s earnings per share (EPS) for the last quarter?

Eli Lilly and Co. EPS for the last quarter amounts to 6.21 USD, increased 480.37 % YoY.

arrow icon

What changes have occurred in the market's expectations for Eli Lilly and Co (LLY)'s fundamentals?

The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 3.06% over the past three months. During the same period, the stock price has changed by 47.56%.
arrow icon

How many employees does Eli Lilly and Co (LLY). have?

Eli Lilly and Co (LLY) has 47000 emplpoyees as of November 19 2025.

arrow icon

What is Eli Lilly and Co (LLY) market cap?

Today LLY has the market capitalization of 973.79B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free